Golgi Protein for HCC Diagnosis

Golgi Protein 73 for Diagnosis of HCC in Egyptian Patients

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03039322

Enrollment

Registered

2017-02-01

Start date

2014-12-22

Completion date

2015-12-30

Last updated

2017-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Screening for Hepatocellular Carcinoma

Brief summary

This case-control study was conducted on 90 patients who were equally divided into two groups. Group 1 included 45 patients with HCV-related chronic liver disease without clinical or radiological evidence of HCC (control group), and Group 2 included 45 patients diagnosed to have HCC by Triphasic abdominal CT (patient group). Serum AFP and GP73 were measured using ELISA technique

Interventions

DIAGNOSTIC_TESTSerum Golgi Protein 73

Serum test

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* patients were older than 18 years.

Exclusion criteria

* patients with hepatic focal lesions not due to HCC such as Hemangioma, Hepatic cyst, and liver metastases; patients infected with HIV; patients with any autoimmune disease; or patients with metastatic disease.

Design outcomes

Primary

Measure	Time frame
Golgi protein correlated with presence of HCC	within one year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026